Assessment of serum Resistin in detecting Insulin Resistance and their impact on response to direct acting antiviral in chronic viral hepatitis C patients

Egyptian Liver Journal

Table 2 Comparison between the three groups regarding baseline Fasting blood sugar, fasting insulin, HOMA-IR and resistin

		Groups			ANOVA		TUKEY'S		Test
		Naïve	Relapser	Control	F	P-value	N&R	N&C	R&C
FBS Pre (mg/dl)	Mean ±SD	85 ± 13	83 ± 16	87 ± 13.5	0.16	0.851
Fasting Insulin Pre (μU/ml)	Mean ±SD	29 ± 7.4	17 ± 5.0	5.9 ± 1.8	59.9	< 0.001	< 0.001	< 0.001	< 0.001
HOMA Pre	Mean ±SD	6.33 ± 2.2	3.5 ± 1.1	1.25 ± 0.4	36.2	< 0.001	< 0.001	< 0.001	0.001
Resistin Pre (ng/L)	Mean ±SD	1715.000 ± 514.807	1735.000 ± 707.869	353.000 ± 85.512	24.209	<0.001	0.99	<0.001	<0.001

This table shows no statistically significant difference between the studied groups before treatment as regard fasting blood sugar. Yet as regard Pre-treatment fasting insulin, HOMA IR & resistin, they were found to be statistically significantly higher in naïve and relapse groups in comparison to control group with P-value <0.001, and fasting insulin, HOMA IR were higher in naïve group in comparison to Relapsers with P-value <0.001